Eptifibatide
Generic Name: eptifibatide
Brand Names:
Eptifibatide
Eptifibatide is a cyclic heptapeptide antiplatelet agent that binds to platelet glycoprotein receptors and inhibits platelet aggregation through a reversible mechanism.
Overview
Eptifibatide is a cyclic heptapeptide antiplatelet agent that binds to platelet glycoprotein receptors and inhibits platelet aggregation through a reversible mechanism.
Uses
Treatment of acute coronary syndrome and patients undergoing percutaneous coronary intervention to decrease the rate of death or new myocardial infarction.
Dosage
Initial 180 mcg/kg IV bolus followed by 2 mcg/kg/min infusion. Reduced to 1 mcg/kg/min for renal impairment (CrCl below 50 mL/min).
Side Effects
Bleeding and hypotension are the most commonly reported adverse reactions. Major bleeding occurred in 10.8% of eptifibatide-treated ACS patients versus 9.3% placebo.
Interactions
Avoid concurrent GP IIb/IIIa inhibitors. Increased bleeding risk with antiplatelet agents, thrombolytics, and heparin.
Warnings
Bleeding is primary concern; requires monitoring of aPTT/ACT. Thrombocytopenia risk exists. Contraindicated in active abnormal bleeding within 30 days, severe uncontrolled hypertension, major surgery within 6 weeks, and hemorrhagic stroke history.
Frequently Asked Questions
What is Eptifibatide used for?▼
Treatment of acute coronary syndrome and patients undergoing percutaneous coronary intervention to decrease the rate of death or new myocardial infarction.
What are the side effects of Eptifibatide?▼
Bleeding and hypotension are the most commonly reported adverse reactions. Major bleeding occurred in 10.8% of eptifibatide-treated ACS patients versus 9.3% placebo.
What are the important warnings for Eptifibatide?▼
Bleeding is primary concern; requires monitoring of aPTT/ACT. Thrombocytopenia risk exists. Contraindicated in active abnormal bleeding within 30 days, severe uncontrolled hypertension, major surgery within 6 weeks, and hemorrhagic stroke history.
Related Medications
Potassium Acetate
potassium acetate
DESCRIPTION Potassium Acetate Injection, USP (2 mEq/mL) is a sterile, nonpyrogenic, concentrated solution of potassium acetate in water for injection. The solution is administered after dilution by the intravenous route as an electrolyte replenisher. It must not be administered undiluted. Each mL contains 196 mg of potassium acetate which provides 2 mEq each of potassium (K + ) and acetate (CH 3 COO − ). The solution may contain acetic acid for pH adjustment. The pH is 6.2 (range: 5.5 to 8.0).
Mesalamine High Density
mesalamine high density
Dosage form: POWDER. Active ingredients: MESALAMINE (1 kg/kg). Category: BULK INGREDIENT.
Water Solution
water solution
Purpose Eyewash
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.